ABOUT GlobeImmune
NEWSROOM
CAREERS
CONTACT US
INVESTORS
Platform
Product Pipeline
Tarmogen Platform
Cancer
Oncology Pipeline
GI-4000 / Mutated Ras
GI-6207 / CEA
GI-6301 / Brachyury
Infectious Disease
Infectious Disease Pipeline
GS-4774 / HBV
GlobeImmune
|
INVESTORS
| Press Releases
Press Releases
Print
Receive E-mail Alerts
Click here
to receive press releases by email from the company.
Press Releases
Date
Title
08/28/2017
Globeimmune Provides Update on Recent Clinical Trial Developments
03/23/2017
GlobeImmune Announces Majority Stock Sale
11/17/2016
GlobeImmune Announces Updates
07/05/2016
GlobeImmune Announces Delisting and Deregistration of Common Stock
05/12/2016
GlobeImmune Announces Updates and Financial Results for First Quarter 2016
03/16/2016
GlobeImmune Announces Updates and Financial Results for Full Year 2015
11/13/2015
GlobeImmune Announces Third Quarter 2015 Results and Corporate Highlights
08/14/2015
GlobeImmune Announces Second Quarter 2015 Results and Corporate Highlights
08/13/2015
GlobeImmune Engages Cantor Fitzgerald as Financial Advisor to Assist With Evaluation of Strategic Options
08/04/2015
UPDATE – Celgene Exercises Early Option to Exclusively License GI-6207, a Novel Cancer Immunotherapy
08/04/2015
Celgene Exercises Early Option to Exclusively License GI-6207, a Novel Cancer Immunotherapy
06/10/2015
GlobeImmune Announces Evaluation of Strategic Alternatives and Corporate Restructuring
05/27/2015
GlobeImmune Announces Top Line Results From GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients
05/14/2015
GlobeImmune Announces First Quarter 2015 Results and Corporate Highlights
04/22/2015
GlobeImmune Announces Opening of Randomized Phase 2 Chordoma Trial at National Cancer Institute
03/17/2015
GlobeImmune Announces Program Updates and Financial Results for Full Year 2014
03/02/2015
GlobeImmune to Present at the 27th Annual ROTH Conference
02/03/2015
GlobeImmune to Present at the 17th Annual BIO CEO & Investor Conference
11/12/2014
GlobeImmune Announces Third Quarter 2014 Financial Results
10/17/2014
Updated Chordoma Data From Phase 1 Study of GI-6301 Presented at 2014 Connective Tissue Oncology Society (CTOS) Annual Meeting
09/30/2014
GlobeImmune to Present at the 13th Annual BioInvestor Forum
09/18/2014
GlobeImmune to Present at the 21st Annual NewsMakers in the Biotechnology Industry Investment Conference
09/03/2014
GlobeImmune to Present at the Aegis Capital Corp. 2014 Healthcare Conference
07/01/2014
GlobeImmune Announces Pricing of Initial Public Offering